Donald J. Vander Griend, Ph.D. - 2009 Young Investigator Award
Function of the Stem Cell Marker CD133 in the Progression of Castrate-resistant Prostate Cancer
Awarded a $75,000 2009 Young Investigator Award
There is a growing paradigm demonstrating that cancer lethality is the result of the hierarchical expansion of "cancer stem cells" which function as stem-like cells to maintain malignant growth. In prostate cancer, such cancer stem cells are thought to contribute to cancer relapse after hormone therapy. The stem cell marker CD133 has been documented to mark prostate cancer stem cells, but little is known regarding its function and clinical relevance in prostate cancers. The aim of this proposal is to address whether CD133 is a viable target for the development of new methods to predict prostate cancer recurrence as well as new therapies to treat prostate cancers.
The Cancer Research Foundation has focused attention on cancer and raised money for life-giving research. We...pay tribute to the scientists who have dedicated themselves to finding a cure and to meet the young researchers who are the next generation of fighters against this disease. The message we send today is that those who suffer from cancer are not alone and that together we can work toward a solution."Richard M. Daley
Mayor, City of Chicago
May 20, 1997